Clinical Trial Update: Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI [Phase 2]

View source ↗

Summary

Phase 2 trial investigating Zorifertinib with intra-Ommaya CSF chemotherapy for leptomeningeal progression in non-small cell lung cancer after a third-generatio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leptomeningeal Metastasis
• Non-small Cell Lung Cancer

Drugs mentioned

• Zorifertinib (Zorifertinib)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: NSCLC (Non-small Cell Lung Carcinoma), Leptomeningeal Metastasis | Phase 2 | Status: NOT_YET_RECRUITING